Lexicon Pharmaceuticals Inc
LXRXHealthcare|Biotechnology|USA
$2.23
-0.03 (-1.33%)
Tangible Book
$0.37
About
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Stock Price
+97.3%(1Y)
Pipeline Summary
68 total trials28
Phase 1
20
Phase 2
20
Phase 3
0
Phase 4
Recruiting: 4Completed: 56Active: 1NOT_YET_RECRUITING: 1Terminated: 4Unknown: 1Withdrawn: 1
Active Trials (5)
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
NCT06217302Diabetic Nephropathies
Phase 3Recruiting
Enrollment: 150 participants
Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
NCT06435156Type 1 Diabetes
Phase 2Recruiting
Enrollment: 320 participants
Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
NCT05696366Type 1 Diabetes
Phase 1Phase 2Active
Enrollment: 24 participants
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891Obstructive Cardiomyopathy, Hypertrophic
Phase 3Recruiting
Enrollment: 500 participants
Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
NCT06933056Platelet Function and Reactivity Tests
Early P1Recruiting
Enrollment: 20 participants
BioScore
5.4/10
Watchlist
Ownership
Recent Insider Trades
DEBBANE RAYMONDBUY
2026-02-252,000 shares @ $1.49
DEBBANE RAYMONDBUY
2026-02-23100,000 shares @ $1.47
DEBBANE RAYMONDBUY
2026-02-20150,000 shares @ $1.47
DEBBANE RAYMONDBUY
2026-02-18268,497 shares @ $1.31
Invus Global Management, LLCBUY
2026-02-021,538,462 shares @ $1.3
Data last updated: Jul 13, 2026, 12:48 PM